论文部分内容阅读
目的:探讨阿奇霉素治疗儿童支原体肺炎的临床疗效和安全性。方法:80例肺炎支原体肺炎患儿随机分为观察组和对照组,每组各40例,观察组采用阿奇霉素治疗,对照组给予红霉素,2周后观察疗效。结果:观察组在体温恢复时间、咳嗽消失时间、肺部啰音消失时间和细菌转阴率方面,均好于对照组,二者比较,差异具有统计学意义(P<0.05);观察组总有效率为92.5%,对照组总有效率77.5%,二者比较具有显著性差异(P<0.05);观察组药物不良反应发生率为15.0%,对照组药物不良反应发生率为20.0%,二者比较无统计学意义(P>0.05)。结论:阿奇霉素治疗儿童支原体肺炎可以快速改善症状、治疗效果好、毒副反应小,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of azithromycin in the treatment of children with mycoplasma pneumonia. Methods: Eighty children with Mycoplasma pneumoniae pneumonia were randomly divided into observation group and control group, 40 cases in each group. The observation group was treated with azithromycin and the control group was given erythromycin. The therapeutic effect was observed after two weeks. Results: The observation group was better than the control group in the recovery time of body temperature, the time of cough disappearance, the time of pulmonary rales disappearance and the rate of bacterial negative conversion. The difference between the two groups was statistically significant (P <0.05) The effective rate was 92.5% in the control group and 77.5% in the control group, with significant difference (P <0.05). The adverse drug reaction rate in the observation group was 15.0% and that in the control group was 20.0% There was no statistical significance (P> 0.05). Conclusion: Azithromycin treatment of children with mycoplasma pneumonia can quickly improve the symptoms, the treatment effect is good, the side effects are small, worthy of clinical application.